Dr. Quintanilla-Martinez is Professor of Pathology and Senior hematopathologist at the University hospital Tübingen´s Institute for Pathology since 2008. Dr. Quintanilla-Martinez received her MD from the National University of Mexico. She did her training in Internal Medicine and Pathology at the National Institute of Nutrition and Science in Mexico City. She completed her fellowships in hematopathology at University Hospital in Minneapolis, Minnesota, Sowthwestern Medical School and Harvard University/Massachusetts General Hospital. She did her fellowship in molecular pathology at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda. She has received several awards including the Rokitansky prize from the Austrian Society of Pathology, The Charlotte-Bühler Stipendium in Austria, the Fogarty Award from the NIH and a Mantle cell lymphoma grant from the Lymphoma Research Foundation.

Dr. Choi completed his residency in Anatomic Pathology and a fellowship in hematopathology at the Hospital of the University of Pennsylvania. Upon completion, he joined the Department of Pathology at the Hospital of University of Pennsylvania as a hematopathologist.  After three years, he was recruited and moved 100 yards to establish a pediatric hematopathology program at the Children’s Hospital of Philadelphia. After 10 years and successfully building a highly regarded pediatric hematopathology service, Dr. Choi was recruited and moved to St. Jude Children’s Research Hospital in Memphis, Tennessee, where he maintained a top pediatric hematopathology service and established clinical flow-based minimal residual disease (MRD) assays for national acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) protocols.  After 9 years, he was recruited to UAB.

Dr. Choi has published over 100 peer reviewed articles and over 20 book chapters with two main research focuses. Early in his career, his focus was more bench science based and focuses on increasing our understanding of the transcription factor TCF3 and its relationship to normal and leukemic B cell development. His current research focus is clinically based and applies new approaches to diagnose difficult pathologic entities.  He has two patents and has been involved in several clinical trials on oncology related drug research throughout his career. His teaching and lecturing resume is extensive.